Homeida M, Halliwell M, Branch R A
Clin Pharmacol Ther. 1978 Aug;24(2):228-32. doi: 10.1002/cpt1978242228.
Liver volume and antipyrine disposition have been investigated in healthy premenopausal women who received 30 microgram ethinyl oestradiol + 500 microgram dl-norgesterol as an oral contraceptive. Six months' treatment was associated with a 17% increase in liver volume while no change occurred in age-matched control subjects. In the same subjects the contraceptive decreased antipyrine clearance by 21%. Thus the contraceptive markedly reduced drug-metabolizing activity per unit volume of liver by 33%. In additional subjects, discontinuation of the contraceptive resulted in a 30% increase in antipyrine clearance. These observations confirm that conventional oral contraceptive therapy to premenopausal women increases hepatic size and that it is a potent inhibitor of drug-metabolizing activity.
对接受30微克炔雌醇+500微克左炔诺孕酮作为口服避孕药的健康绝经前女性的肝脏体积和安替比林处置情况进行了研究。六个月的治疗使肝脏体积增加了17%,而年龄匹配的对照受试者则无变化。在同一批受试者中,该避孕药使安替比林清除率降低了21%。因此,该避孕药使每单位肝脏体积的药物代谢活性显著降低了33%。在另外的受试者中,停用该避孕药导致安替比林清除率增加了30%。这些观察结果证实,对绝经前女性进行常规口服避孕药治疗会增加肝脏大小,并且它是药物代谢活性的强效抑制剂。